NYBA Board Members Sharon Mates and Barbara Dalton to be honored at the Winners' Circle Awards Celebration Dinner
Date:26-Oct-2009
NYBA Board Members Sharon Mates and Barbara Dalton to be honored at the Winners' Circle Awards Celebration Dinner
New York—Oct 26, 2009—The New York Biotechnology Association (NYBA) is pleased to announce that NYBA chairman Dr. Sharon Mates (Chairman and CEO, Intra-Cellular Therapies, Inc.) and NYBA Board member Dr. Barbara Dalton (Vice President for Venture Capital, Pfizer) have been named the honorees for Springboard Enterprises’ 2009 Winners' Circle Awards Celebration Dinner to be held at the New York Stock Exchange on October 29.
“NYBA is pleased and proud to have two of our own honored by Springboard Enterprises,” said Nathan Tinker, executive director of NYBA. “The commitment of Dr. Mates and Dr. Dalton to the biotechnology community is clear, and their support for women entrepreneurs is well known. NYBA congratulates them both on this achievement and award.”
The third annual 2009 Winners' Circle Awards Celebration Dinner, created by Venture-Catalyst Springboard Enterprises, is held in recognition of entrepreneurial women and the community that supports them. The awards dinner is the culmination of the venture capital forum “AllThingsLifeSciences 2009”.
Dr. Mates is the Chairman and CEO of Intra-Cellular Therapies, Inc. (ITI) and also serves as the Chairman of NYBA. From 1989 to 1998, Dr. Mates was the President of North American Vaccine and its predecessor companies. Since 1998, Dr. Mates has been involved in the formation of several biotech and healthcare companies. Intra-Cellular Therapies was formed in 2002 by Dr. Mates along with Dr. Paul Greengard and Dr. Allen Feinberg of Rockefeller University to develop new therapeutics for CNS diseases based on proprietary technologies developed in Dr. Greengard's laboratory. Dr. Mates was named Chairman of NYBA in 2008.
Barbara Dalton, PhD, is Vice President for Venture Capital at Pfizer and leads Pfizer Venture Investments with interests in a broad range of therapeutics from small molecules to biopharmaceuticals and vaccines as well specialty pharmaceuticals, diagnostics, drug delivery and health care technologies. She has been a member of NYBA’s Board of Directors since 2008.
The reception begins at 5:30pm with dinner to follow. Table sponsorships range from $50,000 to $10,000. Individual tickets are $1000.
